The TriSalus™ investigational platform delivers a novel therapeutic (SD-101) directly to the site of disease using a proprietary pressure-enabled infusion method. We believe this approach will stimulate the immune system, thereby enabling improved efficacy of systemic immunotherapies like checkpoint inhibitors or cell therapy.
With patients at the center of all we do and leading oncology experts driving our mission, TriSalus is conducting robust clinical trial programs to evaluate our targeted approach. Our investigators care for cancer patients each day and are driven to seek new treatment options for patients with liver and pancreatic tumors.
Information on TriSalus clinical trials in liver and pancreatic cancers, including information for healthcare providers and patients interested in participating in any ongoing clinical trials, can be found at www.clinicaltrials.gov.
Medical professionals may also email us at firstname.lastname@example.org for more information about study participation.
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-Oncology (PERIO™-01), with Checkpoint Blockade in Adults With Metastatic Uveal Melanoma.
For additional information, including study sites, please visit periotrial.com.
A clinical trial is a study that is conducted to evaluate the safety and effectiveness of a new therapy. Clinical trials are regulated by the FDA in the US.
TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.
Thank you for visiting our site.